Literature DB >> 3209706

HMFG-2 as a prognostic indicator in superficial bladder cancer.

I G Conn1, J Crocker, L A Emtage, D M Wallace.   

Abstract

A series of transitional cell carcinomas and mucosal biopsy specimens of bladder were stained immunohistochemically with the monoclonal antibody HMFG-2. Staining characteristics ranged from luminal staining in well differentiated, superficial lesions to staining of all cells in invasive carcinomas. Invasive tumour nests also stained strongly with the antibody. There was good correlation between the staining pattern and histological assessment of both tumours and mucosal biopsy specimens. Correlation with clinical course showed that it was also a good predictor of subsequent disease progression of superficial tumours. It is suggested that HMFG-2 staining is a sensitive indictor of malignant transformation and that it may have a role as an adjunct to conventional histological examination in the assessment of urothelial carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3209706      PMCID: PMC1141729          DOI: 10.1136/jcp.41.11.1191

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

Review 1.  Immunoperoxidase technique in histopathology: applications, methods, and controls.

Authors:  E Heyderman
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

2.  A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue.

Authors:  E Heyderman; K Steele; M G Ormerod
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

3.  Site of bladder-tumour recurrence.

Authors:  P J Boyd; K G Burnand
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.

Authors:  J Taylor-Papadimitriou; J A Peterson; J Arklie; J Burchell; R L Ceriani; W F Bodmer
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

5.  Correlation between numbers of desmosomes and the aggressiveness of transitional cell carcinoma in human urinary bladder.

Authors:  J Alroy; B U Pauli; R S Weinstein
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

6.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

7.  Distribution of epithelial membrane antigen in normal and neoplastic tissues and it value in diagnostic tumor pathology.

Authors:  J P Sloane; M G Ormerod
Journal:  Cancer       Date:  1981-04-01       Impact factor: 6.860

8.  Ta and T1 bladder cancer: location, recurrence and progression.

Authors:  N M Heney; B N Nocks; J J Daly; G R Prout; J B Newall; P P Griffin; T L Perrone; W A Szyfelbein
Journal:  Br J Urol       Date:  1982-04

9.  Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.

Authors:  O Dalesio; C C Schulman; R Sylvester; M De Pauw; M Robinson; L Denis; P Smith; G Viggiano
Journal:  J Urol       Date:  1983-04       Impact factor: 7.450

10.  A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.

Authors:  E Heyderman; I Strudley; G Powell; T C Richardson; J L Cordell; D Y Mason
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

View more
  6 in total

1.  Modulation of the cluster 1 and mucin antigens in human small cell lung cancer and other epithelial tumour cell lines after treatment with the differentiation inducing agent, sodium butyrate.

Authors:  F G Hay; L W Duncan; S P Langdon; R C Leonard
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.

Authors:  J Zorzos; D V Skarlos; P Pozatzidou; A Zizi; A Bakiras; S Koritsiadis; D Pectasidis; P Koutsioumba; A A Epenetos; M Likourinas
Journal:  Urol Res       Date:  1994

3.  Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody.

Authors:  J Malamitsi; J Zorzos; A D Varvarigou; S Archimandritis; C Dassiou; D V Skarlos; P Dimitriou; M Likourinas; A Zizi; C Proukakis
Journal:  Eur J Nucl Med       Date:  1995-01

4.  Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody.

Authors:  J Malamitsi; J Zorzos; A D Varvarigou; S Archimandritis; C Dassiou; G Sivolapenko; D V Skarlos; A Serefoglou; M Lykourinas; C Proukakis
Journal:  Cell Biophys       Date:  1994

5.  Prognostic significance of mucin expression in urothelial bladder cancer.

Authors:  Slavica Stojnev; Ana Ristic-Petrovic; Ljubinka Jankovic Velickovic; Miljan Krstic; Dragan Bogdanovic; Do Throng Khanh; Ana Ristic; Irena Conic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.

Authors:  Daniel P Vang; Gregory T Wurz; Stephen M Griffey; Chiao-Jung Kao; Audrey M Gutierrez; Gregory K Hanson; Michael Wolf; Michael W DeGregorio
Journal:  J Vis Exp       Date:  2013-10-30       Impact factor: 1.355

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.